Text Size

Integrated Whole-Genome Analysis of Hematologic Disorders

This study is currently recruiting participants.
Verified December 2012 by Stanford University
Sponsor:
Information provided by (Responsible Party):
Stanford University
ClinicalTrials.gov Identifier:
NCT01108159
First received: April 19, 2010
Last updated: December 7, 2012
Last verified: December 2012
History of Changes
  Purpose

To identify mutations, changes in DNA copy number, structural rearrangements, or altered microRNA/mRNA expression that are important for the initiation, progression, or treatment response of hematologic disorders.


Condition Intervention
Hematologic Diseases
 Procedure: Blood Draw
Procedure: Skin Biopsy

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Integrated Whole-Genome Analysis of Hematologic Disorders Using High-Throughput Sequencing and Array Technologies

Resource links provided by NLM:

MedlinePlus related topics: Blood Disorders
U.S. FDA Resources

Further study details as provided by Stanford University:

Biospecimen Retention:   Samples With DNA

blood, bone marrow, skin biopsy


Estimated Enrollment: 100
Study Start Date: September 2009
Estimated Primary Completion Date: December 2017 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

participants with hematologic disorders

Criteria

Inclusion Criteria:

  1. 18 years of age or older
  2. Patient meets the clinical and/or pathologic criteria for the hematologic disorder being examined.
  3. Patient is willing to provide a skin biopsy and five 10 mL tubes of peripheral blood.

Exclusion Criteria:

  1. Less than 18 years of age
  2. Patient is not willing to provide a skin biopsy and five 10 mL tubes of peripheral blood.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01108159

Contacts
Contact: Jason D Merker (650) 922-1885 jdmerker@stanford.edu

Locations
United States, California
Stanford University School of Medicine Recruiting
Stanford, California, United States, 94305
Contact: Jason D Merker     650-922-1885     jdmerker@stanford.edu    
Contact: Cancer Clinical Trials Office     (650) 498-7061        
Principal Investigator: James L Zehnder            
Sub-Investigator: Scott Boyd            
Sub-Investigator: Athena M. Cherry            
Sub-Investigator: Andrew Fire            
Sub-Investigator: Jason Robert Gotlib            
Sub-Investigator: Eleanor L. Marshall            
Sub-Investigator: Jason Merker            
Sub-Investigator: Stephen Tracy Oh            
Sponsors and Collaborators
Stanford University
Investigators
Principal Investigator: James L Zehnder Stanford University
  More Information

No publications provided

Responsible Party: Stanford University
ClinicalTrials.gov Identifier: NCT01108159     History of Changes
Other Study ID Numbers: HEM0013, 1081737-100-DHAAT, SU-09092009-3820, 16329
Study First Received: April 19, 2010
Last Updated: December 7, 2012
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Hematologic Diseases

ClinicalTrials.gov processed this record on May 19, 2013